Erlotinib in non-small cell lung cancer: a review

Author： Blackhall Fiona H Rehman Shazza Thatcher Nicholas

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.6, 2005-06, pp. : 995-1002

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib: A Pharmacoeconomic Review of its Use in Advanced Non-Small Cell Lung Cancer

By Lyseng-Williamson Katherine A.

PharmacoEconomics, Vol. 28, Iss. 1, 2010-01 ,pp. : 75-92

Adis International

Access to resources Recommend Favorite

Reviewing the safety of erlotinib in non-small cell lung cancer

By Reck Martin Mok Tony Wolf Jürgen Heigener David Wu Yi-long

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 147-157

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib: a new therapeutic approach for non-small cell lung cancer

By Bonomi Philip

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1395-1401

Informa Healthcare

Access to resources Recommend Favorite

Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 85-94

Bentham Science Publishers

Access to resources Recommend Favorite

Docetaxel in non-small cell lung cancer: a review

By Davies Angela M Lara Jr Primo N Mack Philip C Gandara David R

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 553-565

Informa Healthcare

Access to resources Recommend Favorite